Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

摘要

This study investigated whether ocrelizumab suppresses MRI-measured and clinically assessed disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) or relapsing multiple sclerosis (RMS); and the results supported ocrelizumab's rapid achievement of those measures.